Publication | Closed Access

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bone DiseaseSclerostinBone HealthOsteopathyGynecologySclerostin Monoclonal AntibodyMedicineOsteoporosisOral Bisphosphonate TherapyPostmenopausal Women